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ABSTRACT 
Objectives: To analyze and compare the clinical, diagnostic, 
and therapeutic features of tuberculosis (TB) in human immuno- 
deficiency virus (HIV)-seropositive and seronegative patients, 
Methods: A 1 -year retrospective review of medical records and 
charts of TB patients admitted to and followed-up at the 
Department of Internal Medicine of the Centre Hospitalier de 
Kigali (CHK), Kigali, Rwanda. 
Results: Tuberculosis was diagnosed in 510 patients. Com- 
plete data, including HIV serologic testing, were available for 
377 patients (74%) of whom 227 were male and 150 female, 
aged 17-70 years (mean, 33 y). Human immunodeficiency virus 
antibodies were detected in 334 (88.6%) of the 377 evaluable 
patients. A definite diagnosis of TB was established in similar 
proportions of Hlkeropositive (66%) and HIV-seronegative 
(63%) patients. The HIV-infected patients differed from the 
patients without HIV infection in the following features: pro- 
portion of patients in the age group 20-39 years (80% vs. 58%; 
P = O.OOl), extrapulmonary manifestations (56% vs. 40%; 
P = 0.045), lower/middle lobe infiltrates (18% vs. 6%; P = 0.07), 
presence of cavities (15% vs. 34%; P = 0.002), pleural dis- 
ease (23 vs. 12%; P = 0.08), tuberculin anergy (67% vs. 26%; 
P < 0.001). After 6 months of anti-TB therapy, both HIV-infected 
and HIV-uninfected patients with smear positive pulmonary TB 
had their sputum samples cleared of acid-fast organisms. 
Adverse drug reactions occurred in 16% and 7% of HIV- 
seropositive and seronegative patients, respectively (P = 0.1 1). 
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The 31% mortality rate (57 of 186) among HIV-infected patients 
who fulfilled the criteria of the World Health Organization (WHO) 
clinical case definition for acquired immunodeficiency syndrome 
(AIDS) was significantly higher than the 7% mortality rate (5 of 
76) in HIV-infected patients who did not meet these criteria 
(P = 0.001) and the 12% mortality rate (5 of 43) in those with- 
out HIV infection (P = 0.003). 
Conclusions: Active TB was strongly associated with HIV infec- 
tion in urban Rwanda. The clinical and radiographic presenta- 
tion of TB, described in HIV-seropositive patients hospitalized 
at the CHK, is most frequently atypical and highly suggestive 
of advanced HIV disease. 
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Nearly 80% of the 4 million people co-infected with 
human immunodeficiency virus (HIV) and Mycobac- 
terium tuberculosis worldwide are living in Africa.l If 
the 5 to 8% incidence rate of active tuberculosis (TB) is 
applied to these individuals,2-5 then 150,000 to 240,000 
additional new cases of TB are expected to occur annu- 
ally in sub-Saharan Africa. 
Inferential information on the increasing burden of 
HIV-associated TB in Rwanda included a 180% increase 
in reported cases of TB between 1983 and 1989,” high 
HIV seroprevalence rates among TB patients,“-’ and rel- 
ative risk of developing active TB of 18 times greater for 
HIV-infected persons than individuals without HIV infec- 
tion, according to one report,5 and 23 times greater, 
according to another.* 
In Rwanda, the annual risk of TB infection is esti- 
mated at 1 .8%, and the prevalence of TB infection exceeds 
50%.9 This high level of TB endemicity coexists with 1.7% 
and 17.8% prevalence rates of HIV infection in rural and 
urban areas, respectively.” Predictions based on a math- 
ematic model developed by Schulzer and associates,” 
using available data on the epidemiology of TB and HIV 
infections in Africa, are consistent with 25,000 new cases 
of TB by the year 2000 for Rwanda. Increased awareness 
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of the clinical pattern of HIV-associated TB is therefore 
of critical importance to lowering the rate of mortality 
from TB and to reducing the spread of this disease within 
the community and the hospital. The recommendations 
issued by the National TB Control Programme for the 
management of TB cases deal mainly with the diagnosis 
and the treatment of pulmonary TB, the most hazardous 
form of the disease.i2 However, extrapulmonary involve- 
ment and atypical radiographic abnormalities are frequent 
manifestations of HIV-associated TB.13-ls These unusual 
features can be mistakenly attributed to diseases other 
than TB, hence increasing the mortality rate through fail- 
ure to establish an early diagnosis of TB.16:17 
Most available descriptions of the clinical presenta- 
tion of TB in HIV-infected patients have focused on 
patients attending TB treatment centers. Thus, they are 
strongly biased toward the description of clinical and 
chest radiographic manifestations of pulmonary TB.“,i9 
This report presents the clinical, diagnostic, and thera- 
peutic features from 377 HIV-infected and uninfected TB 
patients admitted to and followed-up at the Department 
of Internal Medicine of the Centre Hospitalier de Kigali 
(CHK), Kigali, Rwanda. 
PATIENTS AND METHODS 
The CHK is one of the three main referral hospitals of 
Rwanda. It has a capacity of 500 beds of which 120 
belong to the Department of Internal Medicine. At the 
time of this study, the bed occupation rate exceeded 
160% in this department. The prevalence of HIV infection 
was over 60% in patients admitted to medical wards.‘O 
The medical records and charts of all patients newly 
diagnosed as having TB between January 1 and December 
31, 1991, were reviewed and analyzed with regard to 
demographic data, clinical and chest radiographic fea- 
tures, as well as clinical course and response to therapy. 
Particular attention was paid to signs and symptoms 
included in the World Health Organization (WHO) clini- 
cal case definition for acquired immunodeficiency syn- 
drome (AIDS).‘i Results of mycobacterial studies and 
histopathologic examination were extracted from the reg- 
istries of relevant laboratories. 
Patients with proven TB had to meet the following 
criteria: a positive culture for M. tuberculosis from any 
specimen (sputum, body fluid, or tissue) or detection of 
acid-fast bacilli (AFB) on smears from any of the above 
specimens or histopathologic examination demonstrating 
caseating granulomata with or without the presence of 
AFB. The diagnosis was likely in patients with respiratory 
and systemic symptoms suggestive of TB. For pulmonary 
cases, the symptoms consistent with the diagnosis of TB 
included cough for more than 15 days, fever, weight loss, 
chest pain, and pulmonary infiltrate resistant to conven- 
tional antibiotics but showing a good response to anti-TB 
treatment. The diagnosis of pleural and pericardial TB was 
presumed on the presence of a lymphocytic exudate 
resorbing under anti-TB chemotherapy. 
A tuberculin skin test was performed in the major- 
ity of the patients by intradermal injection of 5 tuber- 
culin units (TU) of purified protein derivative (PPD) of 
tuberculin (equivalent to 2U of PPD RT23). The test was 
read 48 to 72 hours postinjection and was considered 
positive in the presence of an induration of 10 mm or 
more in diameter. 
Consenting patients were offered HIV serologic test- 
ing. Human immunodeficiency virus antibodies were 
detected using an enzymatic immunoassay (EJA, Vironos- 
tika Organon Tekhnika, Boxtel, The Netherlands). Sera 
reactive to EL4 were further confirmed by an indirect 
immunofluorescent assay (IFA, Serofluor, Virion, Zurich, 
Switzerland). Discordant results between EL4 and IFA 
were examined by Western blot (Biotech, DuPont de 
Nemours, Wilmington, DE). A positive test was defined 
by the presence of at least one reactive band to HIV core 
protein and one reactive band to HIV envelope protein. 
Most patients received a standard short-course 
chemotherapy regimen of 6 months of daily isoniazid 
and rifampin with daily pyrazinamide and ethambutol 
for the first 2 months of therapy This was followed by 
rifampin and isoniazid twice weekly for the 4-month 
continuation phase. As the Rwandan National TB/Lep- 
rosy Control Programme was being integrated into the 
health care system, a few patients were inadvertently 
prescribed the former, long, standard chemotherapy regi- 
men consisting of 12 months of daily isoniazid and etham- 
butol with daily streptomycin for the first 2 months of 
treatment. 
Differences in proportions were compared by chi- 
square and Fischer’s exact tests and comparison of means 
by Student’s t-test for normally distributed values. The 
Mann-Whitney test was used for the comparison of means 
from abnormally distributed values (P < 0.05 was con- 
sidered to indicate significance). 
RESULTS 
Demographic Data, Clinical and Chest Radiographic 
Findings 
Of the 510 patients admitted to the Department of Inter- 
nal Medicine during the study period, 377 (74%) consented 
to HIV serologic testing and form the basis of this retro- 
spective review. Of these, 334 (88.6%) were HlV-seropos- 
itive. Median ages of HIV-infected and uninfected patients 
were similar (33.1 and 33.6 y). Table 1 shows the distrib- 
ution by HIV serostatus, sex, and age group of the study 
population. Sixty percent of the patients were male. There 
was no difference in HIV seropositivity rate between male 
and female patients (91% and 87%, respectively). Patients 
24 International Journal of Infectious Diseases / Volume 1, Number 1, July 1996 
Table 1. Distribution of the Study Population by Sex and 
Age Group 
HIV-Seropositive HIV-Seronegative 
Characteristic Patients n = 334 (%) Patients n = 43 (%) P Value 
Gender 
Male 197 (59) 30 (70) 0.2 
Female 137 (41) 13 (30) 
Age group (Y) 
< 20 4 (1) 5 (12) 0.001 
20-39 266 (80) 25 (58) 0.0015 
40-59 60 (17) 12 (27) 0.11 
> 60 4 (1) 1 (2) 
of the 20 to 39 year age group predominated among the 
HIV-seropositive group (P = O.OOl), whereas the HIV- 
seronegative group contained a larger proportion of 
patients aged 20 years or less (P = 0.001). 
Evaluation of the WHO clinical case definition was 
carried out in 349 patients. Of the 323 HIV-infected 
patients, 240 (74%) met the criteria of that definition, as 
did 8 (31%) of 26 patients without HIV infection 
(P < 0.001). 
Table 2 lists the clinical manifestations and chest 
radiographic abnormalities in patients with or without 
HIV infection. The symptoms and signs more significantly 
common in HIV-seropositive than in HIV-seronegative 
patients included fever, weight loss of greater than 10% 
of body weight, peripheral lymph node, persistent diar- 
rhea, oral candidiasis, and active or past history of her- 
pes zoster. Other symptoms such as cough, hemoptysis, 
and chest pain were reported at equal frequency. 
On chest radiographic examination (Table 3) HIV- 
seropositive patients were less likely than patients 
Table 2. Clinical and Chest Radiographic Findings in 334 HIV- 
Seropositive and 43 HIV-Seronegative Patients with Tuberculosis 
H/V- HIV- 
Seropositive Seronegative 
Findings n (%) n (%) P Value 
Clinical 
Fever 281 (84) 30 (65) 0.01 
Weight loss 
>I 0% body weight 270 (80) 29 (67) 0.04 
Cough >15 days 328 (98) 41 (95) 
Chest pain 50 (15) 7 (14) 
Hemoptysis 10 (3) 2 (5) 
Peripheral lymph node 62 (I 8) 3 (7) 0.06 
Diarrhea >I month 56 (17) 2 (5) 0.03 
Oral candidiasis 51 (15) 2 (5) 0.05 
Itchy rash 36 (11) 1 (2) 
Herpes zoster (active or scar) 34 (10) - 0.02 
Meeting WHO CDA* 2401328 (74) 8/26 (31) < 0.0007 
Positive tuberculin skin test 71/274 (26) 22/33 (67) < 0.0001 
Radiographic 
Cavities 53 (15) 15 (34) 0.002 
Lower/middle lobe infiltrates 59 (18) 3 (6) 0.07 
Upper lobe infiltrates 31 (9) 3 (6) 
Bilateral infiltrates 55 (16) 7 (16) 
Pleural effusion 77 (23) 5 (12) 0.08 
MediastinaYhilar adenopathy 42 (12) 4 (9) 
Miliaty infiltrates 25 (7) 2 (5) 
*WHO CDA: World Health Organization clinical definition for AIDS. 
without HIV infection to present with cavitary lesions 
(P = 0.002). Middle/lower (P = 0.07) and pleural disease 
(P = 0.08) tended to be more prevalent in HIV-seropos- 
itive patients. Upper lobe and bilateral involvement and 
miliary infiltrates and intrathoracic adenopathies were 
similarly distributed among the two groups. 
Results of tuberculin skin tests were available for 274 
HIV-infected and 33 HIV-uninfected patients. Seventy-one 
HIV-seropositive patients (26%) had a positive skin test 
compared with 22 patients without HIV infection (66%) 
(P < 0.001). Within the HIV-seropositive group, only 17% 
(33 of 200) of HIV-infected patients who fulfilled the cri- 
teria of the WHO clinical definition for AIDS were able 
to mount a positive reaction, as were 53% (36 of 67) of 
HIV-infected patients who did not meet these criteria (I? 
< 0.001). There was no difference in the prevalence rate 
of tuberculin reactivity between the patients who were 
included in the study and those who were not. 
Diagnosis of ‘Ihberculosis 
The procedures used for the diagnosis of TB are shown 
in Table 3. Tuberculosis was bacteriologically and histo- 
logically proven in 247 (66%) of the 377 cases. The 
proportion of HIV-seropositive patients (65%) with a def- 
inite diagnosis of TB did not differ from that of HIV-sero- 
negative patients (63%). Absence of cavities was strongly 
associated with a low yield of microbiologic examina- 
tion. Of the 68 patients with a cavitary disease, 55 (80%) 
had a positive sputum smear for APB or culture of sputum 
positive for M. tuberculosis compared with only 124 
(40%) of the remaining 309 patients who were not found 
to have cavitary lesions (P < 0.001). The rates of positive 
sputum smear and cultures for M. tuberculosis were sim- 
ilar in HIV-seropositive (84%) and in HIV-seronegative 
(73%) patients with cavitary disease. However, a smear 
negativity rate of 28% (42 of 152) was noted among 
positive sputum cultures from HIV-seropositive patients 
Table 3. Results of Histologic and Microbiologic Studies in 334 
HIV-Seropositive and 43 Seronegative Patients with Tuberculosis 
HIV- HIV- 
Specimen Seropositive Seronegative P Value 
Sputum n = 221 n = 33 
Smear positive; culture positive 110 19 
Smear negative; culture positive 42 1 0.07 
Smear positive; culture negative 6 1 
Other* n=3 n=l 
Culture positive 3 0 
Pleural n = 77 n=5 
Culture of fluid positive 11 1 0.08 
Biopsy culture and/or 
history positive 48 4 
Pericardial n= 15 n=3 
Culture of fluid positive 0 0 
Lymph node n= 14 n=2 
Biopsy culture or 
history positive 14 2 
*Urine (n = 2); cerebrospinai fluid (n = 2). 
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compared to 6% (1 of 17) among positive cultures from 
HIV-seronegative patients (P = 0.07). Overall, TB was 
bacteriologically diagnosed in 158 (7 1%) of the 22 1 HIV- 
infected patients and in 21 (64%) of the 33 HIV-seroneg- 
ative patients, who had a pulmonary infiltrate. 
Site of ‘Ihberculosis 
Table 4 shows the relation between HIV status and sites 
of TB. Although the lungs were the most frequent sites 
of the disease, 186 (56%) of the 334 HIV-infected patients 
presented with extrapulmonary involvement. This rate 
compares to 17 (40%) of the 43 patients without HIV 
infection @ = 0.045). At individual sites, pleural TB was 
found to be the only extrapulmonary site significantly 
associated with HIV infection (P = 0.08). Pericardial 
transferred to other treatment centers. Five HIV-seroneg- 
ative patients (12%) were lost to follow-up as were 63 
(19%) HIV-seropositive patients. A higher mortality rate 
was noted in HIV-seropositive patients; 19% (62 of 334) 
died compared to 12% (5 of 43) without HIV infection. 
This difference was not statistically significant. Within 
the HIV-seropositive group, 31% (57 of 186 patients) 
who fulfilled the criteria of the WHO clinical definition 
for AIDS died. This compares with 7% (5 of 76) of HIV- 
infected patients who did not meet these criteria 
(P = 0.001) and 12% (5 of 43) of patients without HIV 
infection (P = 0.003). All deaths occurred within the 6 
months of therapy. However, the cause of death could not 
be accurately determined because of the retrospective 
design of the study. 
disease, peripheral TB lymphadenitis, miliary TB, and 
intrathoracic lymph node involvement occurred at equal 
frequency in the two groups. 
DISCUSSION 
Treatment and Outcome 
Of the 377 patients, 361 (96%) received the 6-month 
short-course regimen of chemotherapy, and the remaining 
I6 were treated with the long, 12-month course. Sputum 
conversion on smears occurred after 2 months of ther- 
apy in 84% (86 of 92) and 87% (14 of 16) of HIV-seropos- 
itive and seronegative patients, respectively. After 6 
months, clearance of AFB from sputum was achieved in 
both HIV-infected and uninfected patients with smear- 
positive pulmonary TB. However, cultures for mycobac- 
teria were not performed. Three HIV-seronegative patients 
(7%) and 54 HIV-seropositive patients (16%) developed 
adverse drug effects, but not severe enough to dictate the 
modification of the treatment. The signs and symptoms of 
drug-related toxicity in HIV-infected patients included 
rashes (7% of cases), neuritis (5%), arthralgias (4%), and 
jaundice (1%) without significant increase in liver enzymes. 
During the period of treatment, 6 HIV-seronega- 
tive (14%) and 21 HIV-seropositive (5%) patients were 
Table 4. Forms and Sites of Tuberculosis according to 
HIV Serostatus 
HIV-Positive HIV-Negative P Value 
n = 334 (%) n = 43 (%) 
Overall 
Pulmonary 148 (44) 26 (60) 0.045 
Extrapulmonary 113 (33) IO (23) 
Both 73 (21) 7 (16) 
Extrapulmonary sites affected 
Pleural 77 (23) 5 (12) 0.08 
lntrathoracic lymph node 43 (13) 4 (9) 
Miliaty 27 (8) 2 (5) 
Pericarditis 18 (5) 1 (2) 
Peripheral adenitis 14 (4) 2 (5) 
Abdominal 3 1 
Meninges 1 1 
Skeletal 1 1 
Genitourinary tract 2 - 
During the study period, TB accounted for 12% (510 of 
4718) of adult medical admissions to the Department of 
Internal Medicine. This proportion is twice as high as 
the proportion of TB patients who were admitted to med- 
ical wards in Kenya before the HIV epidemic.22 
From 1983 through 1991, a substantial gradual 
increase at first, with a sharp rise thereafter has been 
noted in the yearly number of smear or culture positive 
pulmonary TB at the Centre Hospitalier de Kigali (CHK) 
(Figure 1). This increase may result from a better case- 
fmding rate or the availability of short-course chemother- 
apy regimen through the National TB/Leprosy Control 
Programme. Beginning in January 1990, this program was 
progressively integrated into the health care services and 
may have attracted a substantial number of patients, par- 
ticularly noticeable around the year 1990. Although not 
definitely proven, HIV infection appears to have been an 
important contributing factor for this nearly lo-fold 
increase in TB cases between 1983 and 1991. During the 
same period, the number of cases of HIV-associated cryp- 
tococcal meningitis increased dramatically from one case 
per year in 1983 to two cases per week in 1991.” More- 
over, 80% of the HIV-seropositive patients belong to the 
20- to 39-year-old age group, known to be at the highest 
risk of HIV infection in urban Rwanda.‘O 
The 88.6% HIV prevalence rate is one of the highest 
rates ever reported in TB patients from sub-Saharan 
Africa’* and exceeds the 73% recently found by Elliott 
and associates in a cohort of TB patients in Lusaka, Zam- 
bia.24 Because the HIV status was not determined in 133 
patients (26%), the study population could have been 
biased in favor of HIV-seropositive patients. However, the 
fact that both included and non-included patients had a 
similar rate of tuberculin reactivity (26% and 29%, respec- 
tively), is highly suggestive of the same level of immuno- 
deficiency, probably induced by HIV infection, in the two 
groups of patients. One factor that might explain this 
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Figure 1. Yearly number of new cases of smear, culture positive pul- 
monary tuberculosis, or both, and new cases of cryptococcal menin- 
gitis diagnosed in the Department of Internal Medicine, Centre 
Hospitalier de Kigali (CHK), Rwanda, 1983-l 991. 
high prevalence of HIV infection is the 30% baseline 
HIV prevalence rate among young urban dwellers in 
Rwanda. lo In keeping with this is the large predominance 
of the 29- to 39year-old age group among the HIV- 
seropositive patients. 
The association between HIV infection and extra- 
pulmonary TB proved significant, yet the exclusion of 
133 patients may have resulted in a bias toward extra- 
pulmonary forms. An extrapulmonary site of TB was 
documented in 56% of the 334 HIV-infected patients. 
This figure is similar to that reported by Elliott and col- 
league$* in Lusaka, Zambia, and by Gilks and associ- 
atesz5 in Nairobi, Kenya, among TB patients admitted to 
medical wards of general hospitals. 
Human immunodeficiency virus-seropositive and 
-seronegative patients did not differ in extrapulmonary 
site of disease except for pleural involvement. This is 
explained by the high proportion (39%) of HIV-seroneg- 
ative patients with extrapulmonary involvement, which 
far exceeds the usual 15% that would be expected to 
occur in otherwise immunocompetent patients.‘” The 
high frequency of extrapulmonary TB among the HIV- 
seronegative patients reflects the fact that the Depart- 
ment of Internal Medicine is a tertiary referral service to 
which most pulmonary and TB cases with diagnostic 
problems are referred. Chest radiographic abnormalities, 
such as intrathoracic adenopathy, miliary infiltrate, or 
pleural effusion, could be the manifestations of primary 
TB in HIV-seronegative patients.27~28 Frequent referrals of 
patients with such radiographic features for additional 
investigations may have resulted in bias for extrapul- 
monary disease in the HIV-seronegative group. 
Despite the availability of valuable diagnostic facili- 
ties (i.e., laboratory services), a definite diagnosis of TB 
was not obtained in 34% of cases, which is not signiti- 
candy different from the 26% in Zambian patients reported 
by Elliott and co-workers. 24 Both the infrequency of 
cavitary disease and the predominance of extrapulmonary 
forms accounted for this low proportion of proven 
cases.z4z29 The diagnosis of TB was bacteriologically con- 
firmed in similar proportions in both HIV-infected and 
uninfected patients. However, direct microscopy proved to 
be less sensitive in HIV-seropositive than HIV-seronegative 
patients, a finding consistent with previous reports.24,29 
Thoracocentesis and pleural biopsy previously have 
been shown to be of critical importance for the diagnosis 
of pleural TB.30 Histologic and microbiologic examination 
of pleural tissues provided a definite diagnosis of pleural 
TB in 48 (62%) of the 77 HIV-seropositive patients and in 
four (80%) of the five patients without HIV infection. 
Reports by Voetberg and Lucas in rural Zambia on 
the utility of peripheral lymph node biopsy for the diag- 
nosis of TB lymphadenitis indicate that histologic micro- 
biologic examination of lymph node aspirate and biopsy 
specimens yielded a definite diagnosis in 100% of cases.31 
The confirmation of pericardial TB was possible in 
only five cases through examination and culture of tissues 
and fluid sampled from other accessible sites: pleura in 
two cases and lymph node in three cases. 
In this study, nearly 95% of patients were treated 
with a 6-month course of chemotherapy. Drug-related 
adverse reactions occurred more frequently in HIV- 
infected patients than in patients without HIV infection. 
This observation agrees with previous reports on the 
particular susceptibility of HIV-infected patients to anti- 
TB drug-related toxicity.32 Patients who were HIV- 
seropositive experienced a higher mortality rate than 
HIV-seronegative patients, although the difference was 
not statistically significant. However, the difference in 
mortality rate proved significant between HIV-infected 
patients who fulfilled the criteria of the WHO clinical 
definition for AIDS (31%), HIV-infected patients who 
were found not to meet these criteria (7%) (P = O.OOl), 
and patients without HIV infection (12%) (P = 0.003). 
This observation suggests an association between the 
severity of immunodeficiency and adverse outcome in 
patients with HIV-associated tuberculosis.33 
In summary, this retrospective analysis of 377 TB 
patients hospitalized at the CHK found infection with 
HIV in 334 (88.6%), of whom 266 (80%) were 20 to 39 
years of age. In the HIV-seropositive group, the clinical 
and radiographic presentation was strongly suggestive of 
a disease complicating the late stage of HIV infection. 
Selective referrals to a specialized department such as 
this one explain the unusually large proportion of HIV- 
seronegative patients with extrapulmonary tuberculosis. 
The high frequency of extrapulmonary forms of TB and 
the infrequency of cavitary lesions were the major deter- 
minants of the failure to establish a definite diagnosis of 
TB. The 19% mortality rate experienced by the HIV- 
seropositive patients probably represents a low estimate. 
Indeed, recent autopsy surveys carried out in the Ivory 
Coast and Zaire found TB to be the primary cause of 
death in 41% and 54% of patients who died of AIDS, 
respectively.34s3j Half of these infections were not even 
clinically suspected before death. These autopsy fmdings 
emphasize the importance of making an early diagnosis 
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of TB, followed by a prompt initiation of treatment for 
patients presenting with clinical features suggestive of 
TB in areas where both HIV and M. tuberculosis infec- 
tions are known to be prevalent. 
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